<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970099</url>
  </required_header>
  <id_info>
    <org_study_id>H6820-22194</org_study_id>
    <secondary_id>1R01DK059358-01A2</secondary_id>
    <nct_id>NCT00970099</nct_id>
  </id_info>
  <brief_title>Mechanism of Insulin-Resistant in Lean Non-Diabetics</brief_title>
  <official_title>Mechanism of Exercise Training in Lean Insulin-Resistant Non-Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test the following primary hypothesis:&#xD;
&#xD;
        -  Aerobic exercise training will improve insulin sensitivity in insulin resistant subjects&#xD;
           through changes in the major cellular signaling pathways and and/or their regulators.&#xD;
&#xD;
      Accordingly, the proposed study is designed to accomplish the following specific aims:&#xD;
&#xD;
        -  Quantitate how exercise training improves insulin sensitivity and decreases&#xD;
           cardiovascular risk factors in a general population of lean, nondiabetic, insulin&#xD;
           resistant subjects. Effects on known cardiovascular risk factors including blood&#xD;
           pressure and serum lipoproteins will be evaluated. Change in regional adiposity will&#xD;
           also be measured&#xD;
&#xD;
        -  Determine the effects of a program of regular aerobic exercise on in the insulin&#xD;
           receptor signaling pathway. Biopsies of vastus lateralis muscle from insulin resistant&#xD;
           subjects will be obtained before and after a hyperinsulinemic glucose clamp. This&#xD;
           procedure will take place in the untrained state and after exercise training. The&#xD;
           investigators will measure changes in the insulin receptor and the activity of the major&#xD;
           components of the intracellular insulin signaling pathway. The investigators will also&#xD;
           look intracellular proteins that regulate this signaling pathway.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity and insulin signaling</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 week exercise regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal lifestyle routine with no exercise for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Non exercise</intervention_name>
    <description>subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist</description>
    <arm_group_label>non-exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 20-50&#xD;
&#xD;
          -  No regular exercise for past 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes, Cardiovascular disease, Pregnant or lactating females,BMI &gt;27&#xD;
&#xD;
          -  Medications that may interfere with carbohydrate metabolism - glucocorticoids,&#xD;
             adrenergic agonists, ACE inhibitors, alpha blockers, diuretics, beta blockers, oral&#xD;
             contraceptives, HMG CoA reductase inhibitors&#xD;
&#xD;
          -  History of epilepsy, cancer, hepatitis, active infection, active Graves' disease,&#xD;
             cystic fibrosis, sickle cell anemia, peripheral vascular disease, cerebrovascular&#xD;
             disease, asthma&#xD;
&#xD;
          -  Any medical condition that in the opinion of the investigator will interfere with safe&#xD;
             completion of the trial&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Prior participation in a clinical trial that could potentially alter insulin&#xD;
             sensitivity: e.g., use of new insulin sensitizers&#xD;
&#xD;
          -  HIV seropositive&#xD;
&#xD;
          -  Anemia (Hgb &lt; 12 g/dl)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ucsf Gcrc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <name_title>Ira Goldfine</name_title>
    <organization>UCSF</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

